Inhibition study of rabbit liver cytosolic reductases involved in daunorubicin toxication

References

• Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54: 1–7
   PubMed Web of Science ®Google Scholar
• Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969; 11(6)1101–1110
   PubMed Web of Science ®Google Scholar
• Giannini G. Fluorinated anthracyclines: Synthesis and biological activity. Med Chem Rev—Online 2004; 1: 47–71, (URL: http://www.bentham-mps.org/1-1/mcro1-1/Giuseppe%20Giannini.pdf, 10.8.2004)
   Google Scholar
• Monneret C. Recent developments in the field of antitumour anthracyclines. Eur J Med Chem 2001; 36(6)483–493
   PubMed Web of Science ®Google Scholar
• Cottin Y, Touzery C, Dalloz F, Coudert B, Toubeau M, Riedinger A, Louis P, Wolf JE, Brunotte F. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: Evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998; 21(9)665–670
   PubMed Web of Science ®Google Scholar
• Shadle SE, Bammel BP, Cusack BJ, Knighton RA, Olson SJ, Mushlin PS, Olson RD. Daunorubicin cardiotoxicity: Evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 2000; 60(10)1435–1444
   PubMed Web of Science ®Google Scholar
• Ferrans VJ, Clark JR, Zhang J, Yu ZX, Herman EH. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 1997; 39(10)928–937
   PubMedGoogle Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Eng J Med 1998; 339(13)900–905
   PubMed Web of Science ®Google Scholar
• Hrdina R, Geršl V, Klimtová I, Šimůnek T, Macháčková J, Adamcová M. Anthracycline-induced cardiotoxicity. Acta Medica 2000; 43(3)75–82
   Google Scholar
• Keizer HG, Pinedo HM, Schuurhui GJ, Joenje H. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharm Ther 1990; 47(2)219–231
   PubMed Web of Science ®Google Scholar
• Goeptar AR, Te Koppele JM, Lamme EK, Pique JM, Vermeulen NP. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: A study with rat liver microsomes and purified enzymes. Mol Pharmacol 1993; 44(6)1267–1277
   PubMed Web of Science ®Google Scholar
• Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: Biochemical aspects and pharmacologic implications. Biochem Pharmacol 2003; 66(6)989–998
   PubMed Web of Science ®Google Scholar
• Corna G, Santambrogio P, Minotti G, Cairo G. Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: Role of reactive oxygen species and ferritin. J Biol Chem 2004; 279(14)13738–13745
   PubMed Web of Science ®Google Scholar
• Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 2001; 61(23)8422–8428
   PubMed Web of Science ®Google Scholar
• Cairo G, Recalcati S, Pietrangelo A, Minotti G. The iron regulatory proteins: Targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 2002; 32(12)1237–1243
   PubMed Web of Science ®Google Scholar
• Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek RJ, Olson RD. Daunorubicin-induced cardiac injury in the rabbit: A role for daunorubicinol?. Toxicol Appl Pharmacol 1993; 118(2)177–185
   PubMed Web of Science ®Google Scholar
• Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 1990; 4(13)3076–3086
   PubMed Web of Science ®Google Scholar
• Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 1987; 262(33)15851–15856
   PubMed Web of Science ®Google Scholar
• Pröpper D, Maser E. Carbonyl reduction of daunorubicin in rabbit liver and heart. Pharmacol Toxicol 1997; 80(5)240–245
   PubMedGoogle Scholar
• Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000; 59(3)293–300
   PubMed Web of Science ®Google Scholar
• Forrest GL, Gonzales B. Carbonyl reductase. Chem Biol Interact 2000; 129(1–2)21–40
   PubMed Web of Science ®Google Scholar
• Imamura Y, Higuchi T, Nozaki Y, Sugino E, Hibino S, Otagiri M. Purification and properties of carbonyl reductase from rabbit kidney. Arch Biochem Biophys 1993; 300(2)570–576
   PubMed Web of Science ®Google Scholar
• Miyabe Y, Amano T, Deyashiki Y, Hara A, Tsukada F. Kinetic studies of the inhibition of a human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isozyme by bile acids and anti-inflammatory drugs. Biol Pharm Bull 1995; 18(1)9–12
   PubMed Web of Science ®Google Scholar
• Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y, Ishida N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996; 313: 373–376
   PubMed Web of Science ®Google Scholar
• Flynn TG, Green NC. The aldo-keto reductases: An overview. Exp Med Biol 1993; 328: 251–257
   Google Scholar
• Felsted RL, Bachur NR. Mammalian carbonyl reductases. Drug Metab Rev 1980; 11(1)1–60
   PubMed Web of Science ®Google Scholar
• Penning TM, Mukharji I, Barrows S, Talalay P. Purification and properties of a 3 alpha-hydroxysteroid dehydrogenase of rat liver cytosol and its inhibition by anti-inflammatory drugs. Biochem J 1984; 222(3)601–611
   PubMed Web of Science ®Google Scholar
• Atalla A, Maser E. Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact 2001; 130–132(1–3)737–748
   PubMed Web of Science ®Google Scholar
• Brown RE, Jarvis KL, Hyland KJ. Protein measurement using bicinchoninic acid: Elimination of interfering substances. Anal Biochem 1989; 180(1)136–139
   PubMed Web of Science ®Google Scholar
• Palackal NT, Lee SH, Harvey RG, Blair IA, Penning TM. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J Biol Chem 2002; 277(27)24799–24808
   PubMed Web of Science ®Google Scholar
• Burczynski ME, Lin HK, Penning TM. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: Implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res 1999; 59(3)607–614
   PubMed Web of Science ®Google Scholar
• Varma SD, Mikuni I, Kinoshita JH. Flavonoids as inhibitors of lens aldose reductase. Science 1975; 188(4194)1215–1216
   PubMed Web of Science ®Google Scholar
• Korkina LG, Afanas'ev IB. Antioxidant and chelating properties of flavonoids. Adv Pharmacol 1997; 38: 151–163
   PubMedGoogle Scholar
• Van Acker SABE, Van den Berg DJ, Tromp MNJL, Griffionen DH, Van Bennekom WP, Van der Vijgh WJF, Bast A. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med 1996; 20(3)331–342
   PubMed Web of Science ®Google Scholar
• Van Acker SABE, Van Balen GJ, Van der Berg DJ, Bast A, Van der Vijgh WJF. Influence of iron chelation on the antioxidant activity of flavonoids. Biochem Pharmacol 1998; 56(8)935–943
   PubMed Web of Science ®Google Scholar
• Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, Beauvillain JC, Bailly C. Mitochondrial proliferation during apoptosis induced by anticancer agents: Effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004; 23(42)7018–7030
   PubMed Web of Science ®Google Scholar